Guided Therapeutics (GTHP) Cash & Equivalents (2010 - 2026)

Guided Therapeutics has disclosed Cash & Equivalents across 17 years of filings, most recently posting $12000.0 for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 93.51% year-over-year to $12000.0; the TTM figure through Jun 2026 stood at $12000.0 (down 93.51% YoY), while the FY2025 annual figure was $63000.0, down 83.76% from the prior year.
• Cash & Equivalents came in at $12000.0 for Q2 2026 at Guided Therapeutics, down from $369000.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $2.7 million in Q3 2022 to a low of $12000.0 in Q2 2026.
• Average Cash & Equivalents over 5 years is $712833.3, with a median of $416500.0 recorded in 2024.
• Year-over-year, Cash & Equivalents jumped 398.52% in 2022 and slumped 93.51% in 2026.
• Over 5 years, Cash & Equivalents stood at $2.3 million in 2022, then tumbled by 74.45% to $591000.0 in 2023, then plunged by 34.35% to $388000.0 in 2024, then tumbled by 83.76% to $63000.0 in 2025, then tumbled by 80.95% to $12000.0 in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $12000.0 in Q2 2026, $369000.0 in Q1 2026, and $63000.0 in Q4 2025.